Duncan McKechnie

CIK: 0002062139

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)5 (41.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (25.0%)

Compensation grants

Other (G, F, J, C, D, …)4 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VRTX

VERTEX PHARMACEUTICALS INC / MA

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

VRTX
VERTEX PHARMACEUTICALS INC / MA
Jul 2, 2026
Sale(S)
Direct
1.5K shares at avg. $519.00$800K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Mar 11, 2026
Sale(S)
Direct
2.6K shares at avg. $498.42$1.3M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Mar 4, 2026
Sale(S)
Direct
2.4K shares at avg. $475.30$1.2M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 25, 2026
Sale(S)
Direct
2.4K shares at avg. $489.00$1.2M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 25, 2026
Sale(S)
Direct
2.5K shares at avg. $486.35$1.2M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 24, 2026
Tax Payment(F)
Direct
873 shares at avg. $485.11$424K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 17, 2026
Award(A)
Direct
5K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 17, 2026
Tax Payment(F)
Direct
1.1K shares at avg. $483.75$555K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 13, 2026
Tax Payment(F)
Direct
2.3K shares at avg. $487.76$1.1M
VRTX
VERTEX PHARMACEUTICALS INC / MA
Feb 10, 2026
Tax Payment(F)
Direct
1.1K shares at avg. $468.41$528K
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jan 22, 2026
Award(A)
Direct
4.7K shares-
VRTX
VERTEX PHARMACEUTICALS INC / MA
Jan 22, 2026
Award(A)
Direct
2.1K shares-

		Type	Shares	Price		Ownership
Jul 2, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	1,541	$519.00	$799,779	Direct
Mar 11, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	2,633	$498.42	$1,312,340	Direct
Mar 4, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	2,437	$475.30	$1,158,306	Direct
Feb 25, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	2,410	$489.00	$1,178,490	Direct
Feb 25, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Sale(S)	2,500	$486.35	$1,215,875	Direct
Feb 24, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	873	$485.11	$423,501	Direct
Feb 17, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	4,962	-	$0	Direct
Feb 17, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	1,148	$483.75	$555,345	Direct
Feb 13, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	2,283	$487.76	$1,113,556	Direct
Feb 10, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Tax Payment(F)	1,127	$468.41	$527,898	Direct
Jan 22, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	4,720	-	$0	Direct
Jan 22, 2026	VRTX VERTEX PHARMACEUTICALS INC / MA	Award(A)	2,080	-	$0	Direct

1-12 of 12 transactions

About McKechnie Duncan

McKechnie Duncan (SEC CIK 0002062139) files insider reports with the SEC as EVP, Chief Commercial Officer of VERTEX PHARMACEUTICALS INC / MA (VRTX).

Signal8 holds 9 ownership filings by McKechnie Duncan (1 Form 3, 8 Form 4), filed between Jul 2, 2025 and Jul 7, 2026. Those filings report 12 transactions, from Jan 22, 2026 to Jul 2, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on McKechnie Duncan's filings is in BOSTON, MA.

Recent filings by McKechnie Duncan

Jul 2, 2026: Open-market sale of VRTX shares (Form 4, code S).
Mar 11, 2026: Open-market sale of VRTX shares (Form 4, code S).
Mar 4, 2026: Open-market sale of VRTX shares (Form 4, code S).
Feb 25, 2026: Open-market sales of VRTX shares (2 lines, Form 4, code S).
Feb 24, 2026: Tax withholding of VRTX shares (Form 4, code F).

Other insiders filing for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Brennan Daniel J., Director
SACHS BRUCE I, Director
Garber Alan M, Director
van Grunsven Jasper, EVP, CP and NPPO
Ambrose Kristen, SVP & Chief Accounting Officer
Tatsis Ourania, EVP, Chief Reg. & Quality Off.

How to read Form 4 transaction codes